Anticompetitive mergers in the pharmaceutical industry can undermine consumer welfare, innovation, and market competition. While mergers may improve efficiency and provide resources for growth, they can also eliminate rivals and sustain high prices. A growing concern is “killer acquisitions,” where large firms acquire smaller competitors and halt development of promising products. For instance, Covidien’s 2012 acquisition of Newport Medical Instruments led to the cancellation of a low-cost ventilator project, reducing potential market competition.

U.S. merger oversight under the Hart–Scott–Rodino Act relies on financial thresholds to determine which deals require review, but many pharmaceutical acquisitions fall below these limits—especially when firms’ key assets are intangible, such as patents. As a result, smaller but strategically important deals often escape scrutiny. Evidence suggests that acquisitions involving overlapping products are more likely to result in discontinued development, particularly when unreported.

Although mergers can help small biotech firms bring products to market faster by leveraging larger companies’ resources, consolidation often reduces competitive pressure, weakens bargaining power, and may narrow research priorities. Complex deal structures can also be used to avoid regulatory thresholds while still allowing acquirers to influence or delay competing products.

To address these gaps, policymakers could expand oversight by lowering reporting thresholds in highly concentrated industries, including intangible assets in valuation, and applying stricter review standards to deals involving overlapping products. Requiring firms to demonstrate continued product development and report progress post-merger could further deter anticompetitive behavior.

Strengthening antitrust frameworks in these ways would better align pharmaceutical mergers with innovation goals, fair competition, and patient interests.